Education
About Us
Working with TipRanks
Follow Us
Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179)
:2179
RESEARCH TOOLSreports
2179 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$6.76 - HK$10.00
Previous CloseN/A
Volume13.00K
Average Volume (3M)56.15K
Market Cap
HK$3.76B
Enterprise ValueHK$5.03B
Total Cash (Recent Filing)HK$448.31M
Total Debt (Recent Filing)HK$889.10M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding316,138,700
10 Day Avg. Volume23,300
30 Day Avg. Volume56,150
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.50Price Target Upside-3.72% Downside
Rating ConsensusHold
Number of Analyst Covering0
Jiangsu Recbio Technology Co., Ltd. Class H News
2179 FAQ
What was Jiangsu Recbio Technology Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Recbio Technology Co., Ltd. Class H lowest stock price was HK$6.76 and its highest was HK$10.00 in the past 12 months.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s market cap?
Jiangsu Recbio Technology Co., Ltd. Class H’s market cap is HK$3.76B.
When is Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date?
Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 29, 2025 which is in 6 days.
How were Jiangsu Recbio Technology Co., Ltd. Class H’s earnings last quarter?
Jiangsu Recbio Technology Co., Ltd. Class H released its earnings results on Mar 28, 2025. The company reported -HK$0.706 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.706.
Is Jiangsu Recbio Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangsu Recbio Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Jiangsu Recbio Technology Co., Ltd. Class H pay dividends?
Jiangsu Recbio Technology Co., Ltd. Class H does not currently pay dividends.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate?
Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangsu Recbio Technology Co., Ltd. Class H have?
Jiangsu Recbio Technology Co., Ltd. Class H has 316,138,700 shares outstanding.
What happened to Jiangsu Recbio Technology Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Recbio Technology Co., Ltd. Class H reported an EPS of -HK$0.706 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.314%.
Which hedge fund is a major shareholder of Jiangsu Recbio Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$7.50 (-3.72% Downside)
HK$7.50 (-3.72% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.00%
12-Months-Change
Fundamentals
Return on Equity
-69.97%
Trailing 12-Months
Asset Growth
-14.22%
Trailing 12-Months
Company Description
Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
SinoMab Bioscience Ltd.
―